These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 18461290)

  • 21. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
    Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
    J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methotrexate-associated lymphoproliferative disorders of the tongue developing in patients with rheumatoid arthritis: a report of 2 cases and a review.
    Hashimoto K; Nagao T; Saito T; Kinoshita H
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):e1-5. PubMed ID: 24927637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis.
    Horie N; Kawano R; Kaneko T; Shimoyama T
    Aust Dent J; 2015 Sep; 60(3):408-11. PubMed ID: 25302816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.
    Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A
    Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection.
    Lioté F; Pertuiset E; Cochand-Priollet B; D'Agay MF; Dombret H; Numéric P; D'Anglejan G; Kuntz D
    J Rheumatol; 1995 Jun; 22(6):1174-8. PubMed ID: 7674250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Methotrexate-related lymphoproliferative disease showing different histological findings at recurrence].
    Kato T; Imaizumi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Ichinose K; Miyoshi H; Ohshima K; Miyazaki Y
    Rinsho Ketsueki; 2023; 64(2):97-101. PubMed ID: 36990739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary Adrenal Lymphoma Possibly Associated With Epstein-Barr Virus Reactivation Due to Immunosuppression Under Methotrexate Therapy.
    Ohkura Y; Shindoh J; Haruta S; Kaji D; Ota Y; Fujii T; Hashimoto M; Watanabe G; Matsuda M
    Medicine (Baltimore); 2015 Aug; 94(31):e1270. PubMed ID: 26252293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Methotrexate-associated lymphoproliferative disorders: clinical aspects].
    Tokuhira M; Kizaki M
    Rinsho Ketsueki; 2019; 60(8):932-943. PubMed ID: 31484893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
    Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
    Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unusual manifestation of methotrexate-associated lymphoproliferative disorder as a palatal mass.
    Watanabe T; Teratani Y
    BMJ Case Rep; 2022 Sep; 15(9):. PubMed ID: 36175042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders.
    Tokuhira M; Tamaru JI; Kizaki M
    J Clin Exp Hematop; 2019; 59(2):72-92. PubMed ID: 31257348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.
    Gion Y; Doi M; Nishimura Y; Ikeda T; Filiz Nishimura M; Sakamoto M; Egusa Y; Nishikori A; Fujita A; Iwaki N; Nakamura N; Yoshino T; Sato Y
    Cancer Med; 2022 Jan; 11(2):417-432. PubMed ID: 34842351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases.
    Koens L; Senff NJ; Vermeer MH; Willemze R; Jansen PM
    Am J Surg Pathol; 2014 Jul; 38(7):999-1006. PubMed ID: 24805861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spontaneous remission of methotrexate-associated lymphoproliferative disorder with Epstein-Barr virus type II latency.
    Matsuzaki Y; Minakawa S; Sagara C; Takiyoshi N; Nakano H; Sawamura D
    Eur J Dermatol; 2018 Oct; 28(5):693-694. PubMed ID: 30325313
    [No Abstract]   [Full Text] [Related]  

  • 35. Involvement of Epstein-Barr virus in the development and spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis.
    Kitamura N; Sugiyama K; Nagasawa Y; Hamaguchi M; Kobayashi H; Takei M
    Clin Exp Rheumatol; 2022 Jul; 40(7):1330-1335. PubMed ID: 34369356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder.
    Pina-Oviedo S; Miranda RN; Medeiros LJ
    Am J Surg Pathol; 2018 Jan; 42(1):116-129. PubMed ID: 29112013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis.
    Tokuhira M; Watanabe R; Nemoto T; Sagawa M; Tomikawa T; Tamaru J; Itoyama S; Nagasawa H; Amano K; Kameda H; Takeuchi T; Mori S; Kizaki M
    Leuk Lymphoma; 2012 Apr; 53(4):616-23. PubMed ID: 21933041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EBV-positive mucocutaneous ulcer arising in rheumatoid arthritis patients treated with methotrexate: Single center series of nine cases.
    Satou A; Banno S; Hanamura I; Takahashi E; Takahara T; Nobata H; Katsuno T; Takami A; Ito Y; Ueda R; Nakamura S; Tsuzuki T
    Pathol Int; 2019 Jan; 69(1):21-28. PubMed ID: 30615240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report.
    Nomura M; Sumiya R; Ono H; Nagai T; Kumazawa K; Shimizu A; Endo D; Aoyanagi N
    World J Surg Oncol; 2021 Jan; 19(1):4. PubMed ID: 33388058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.